NCT05719714View on ClinicalTrials.gov

Effect of Dapagliflozin on Metabolomics and Cardiac Mechanics in Chronic Kidney Disease

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

January 16, 2024

Primary Completion Date

March 1, 2026

Study Completion Date

September 30, 2026

Conditions
Chronic Kidney DiseasesHeart Failure With Preserved Ejection FractionKidney DiseasesHeart Failure
Interventions
DRUG

Dapagliflozin 10 MG [Farxiga]

10mg (milligram) tablet to be taken orally once daily for 6 months. Manufacturer: Astrazeneca. Study drug will be stored and dispensed by the Interventional Drug Service Pharmacy at Northwestern University.

Trial Locations (1)

60607

RECRUITING

Northwestern University, Chicago

All Listed Sponsors
collaborator

National Institutes of Health (NIH)

NIH

collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

Northwestern University

OTHER